A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) cells are auxotrophic for arginine, depletion of which leads to tumour regression. The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity of pegylated recombinant human arginase 1 (peg-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yau, Thomas, Cheng, P. N., Chan, Pierre, Chan, William, Chen, Li, Yuen, Jimmy, Pang, Roberta, Fan, S. T., Poon, Ronnie T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553413/
https://www.ncbi.nlm.nih.gov/pubmed/22426640
http://dx.doi.org/10.1007/s10637-012-9807-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553413/
https://www.ncbi.nlm.nih.gov/pubmed/22426640
http://dx.doi.org/10.1007/s10637-012-9807-9

Ejemplares similares